Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sotrovimab - GlaxoSmithKline/Vir Biotechnology

Drug Profile

Sotrovimab - GlaxoSmithKline/Vir Biotechnology

Alternative Names: GSK-4182136; VIR-7831; WBP 2275; Xevudy

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vir Biotechnology
  • Developer GSK; Vir Biotechnology
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed COVID 2019 infections

Most Recent Events

  • 11 Oct 2023 Efficacy and safety data from a phase I COSMIC trial in COVID-2019 infections released by GlaxoSmithKline
  • 21 Jul 2023 GlaxoSmithKline and Vir Biotechnology terminates the phase II COMET-PACE trial in COVID-2019 infections (In infants, In neonates, In children, In adolescents, In adults) in the US, Brazil, Greece, Philippines, and South Africa (IM) (IV), due to decrease in in-vitro neutralization of study drug against circulating SARS-CoV-2 variants (NCT05124210) (EudraCT2021-003717-18)
  • 14 Jul 2023 National Institute of Allergy and Infectious Diseases completes a phase III trial in COVID-2019 infections (Combination therapy) in United Kingdom, Nigeria, Uganda, Singapore, Denmark, Spain, Switzerland, Greece, USA, Poland (IV) (NCT04501978) (EudraCT2020-003278-37)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top